EX-12.1 4 v239025_ex12-1.htm EXHIBIT 12.1 Unassociated Document
Exhibit 12.1
   
ZIOPHARM Oncology, Inc.
Computation of Ratio of Earnings to Fixed Charges
and to Combined Fixed Changes and Preference Dividends
   
Year Ended December 31,
    
Nine Months
Ended
September 30,
  
$ In Thousands, Except Ratio
  
2006
    
2007
    
2008
    
2009
    
2010
    
2011
  
Fixed charges:
                                    
Interest Expense
   $ -     $ -     $ -     $ -     $ -     $ -  
Amortized premiums discounts and capitalized expenses related to indebtedness
     -       -       -       -       -       -  
    $ -     $ -     $ -     $ -     $ -     $ -  
                                                 
Earnings (loss):
                                                
Net income (loss) before tax benefit (provision)
   $ (17,857 )   $ (26,608 )   $ (25,231 )   $ (7,649 )   $ (32,670 )   $ (50,534 )
Add fixed charges
     -       -       -       -       -       -  
    $ (17,857 )   $ (26,608 )   $ (25,231 )   $ (7,649 )   $ (32,670 )   $ (50,534 )
                                                 
Ratio of earnings to fixed charges
     *       *       *       *       *       *  
                                                 
Deficiency of earnings to fixed charges
   $ (17,857 )   $ (26,608 )   $ (25,231 )   $ (7,649 )   $ (32,670 )   $ (50,534 )
 
* Less than one to one coverage